Effects of chronic bacterial prostatitis on prostate specific antigen levels total and free in patients with benign prostatic hyperplasia and prostate cancer

International Urology and Nephrology
Mohammed Nizar G BattikhiQusey Battikhi

Abstract

Prostatic-specific antigen (PSA), a tumor marker helpful in the diagnosis and follow-up of prostate cancer, may rise due to causes such as prostatitis, chronic benign prostatic hyperplasia (BHP), etc. The aim of this study was to investigate the relationship between prostatitis and the level of total and free prostate-specific antigen in patients with no clinical evidence of prostate cancer. A comprehensive urological examination was performed on 156 patients aged 35-61 years old. All patients have symptoms of prostatitis. Prostate fluid culture was preformed. All patients underwent a course of antibacterial treatment after which the levels of total prostate specific antigen (TPSA) and free prostate specific antigen (FPSA) were evaluated. An increase in TPSA (> 4 ng/ml) was observed in 14/24 (58.3%) patients with acute prostatitis and in 7/45 (15.5%) and 4/44 (9.1%) in patients with chronic bacterial prostatitis (CBP) and a bacterial prostatitis, respectively. Low blood concentration of TPSA and FPSA were observed after effective antibacterial and anti-inflammatory treatment therapy in most cases. These data suggested that prostatitis must be considered when interpretation of TPSA and FPSA values as tumor marker.

References

Apr 25, 1991·The New England Journal of Medicine·W J CatalonaG L Andriole
Oct 8, 1987·The New England Journal of Medicine·T A StameyE Redwine
Oct 1, 1989·The Journal of Urology·M A HudsonW J Catalona
Nov 8, 1995·JAMA : the Journal of the American Medical Association·S J JacobsenM M Lieber
Jan 1, 1996·European Urology·V PansadoroS Lauretti
Mar 21, 1998·The Journal of Urology·M M CollinsM J Barry
Sep 11, 1999·International Urology and Nephrology·S ResimG Sevin
Jan 6, 2001·The Journal of Laryngology and Otology·Y RakoverG Rosen
May 16, 2001·Cleveland Clinic Journal of Medicine·J M Potts
Jan 25, 2003·Acta Oto-laryngologica·Juen-Haur HwangTien-Chen Liu
Mar 29, 2003·Prostate Cancer and Prostatic Diseases·A G AnastasiadisR Shabsigh
Jul 5, 2005·Urology·J Curtis Nickel, Timothy Moon
Feb 14, 2006·Nature Clinical Practice. Urology·Richard B Alexander

❮ Previous
Next ❯

Citations

Nov 18, 2006·International Urology and Nephrology·Cuneyt OzdenAli Memis
Aug 29, 2013·International Journal of Medical Sciences·Hatice KaramanDerya Kocer
Oct 19, 2013·The American Journal of Medicine·Pei-Chang LeeChia-Jen Liu
Apr 25, 2018·Journal of Korean Medical Science·Yumi Seo, Gilho Lee

❮ Previous
Next ❯

Related Concepts

Related Feeds

CRISPR & Staphylococcus

CRISPR-Cas system enables the editing of genes to create or correct mutations. Staphylococci are associated with life-threatening infections in hospitals, as well as the community. Here is the latest research on how CRISPR-Cas system can be used for treatment of Staphylococcal infections.